Powered by: Motilal Oswal

News

Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility Aurobindo Pharma is currently trading at Rs. 864.95, up by 2.00 points or 0.23% from its previous closing of Rs. 862.95 on the BSE. The scrip opened at Rs. 864.30 and has touched a high and low of Rs. 868.30 and Rs. 858.75 respectively. So far 27476 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 887.20 on 14-Aug-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility
Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility
Source: Accord Fintech
7/09/2023 12:51:48 PM
Strides Pharma Science shines on getting nod to acquire 100% stake in Strides Pharma Services Strides Pharma Science is currently trading at Rs. 479.80, up by 21.15 points or 4.61% from its previous closing of Rs. 458.65 on the BSE. The scrip opened at Rs. 458.00 and has touched a high and low of Rs. 485.50 and Rs. 458.00 respectively. So far 32126 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 488.85 on 01-Aug-2023 and a 52 week low of Rs. 268.40 on 21-Mar-2023. Last one week high and low of the scrip...
Strides Pharma Science shines on getting nod to acquire 100% stake in Strides Pharma Services
Strides Pharma Science shines on getting nod to acquire 100% stake in Strides Pharma Services
Source: Accord Fintech
7/09/2023 12:05:52 PM
Lupin inches up on collaborating with Mark Cuban Cost Plus Drug Company and COPD Foundation Lupin is currently trading at Rs. 1143.20, up by 4.10 points or 0.36% from its previous closing of Rs. 1139.10 on the BSE. The scrip opened at Rs. 1144.00 and has touched a high and low of Rs. 1148.60 and Rs. 1141.50 respectively. So far 12186 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,148.60 on 7-Sept-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022. Last one week high and low of the scrip stood at Rs...
Lupin inches up on collaborating with Mark Cuban Cost Plus Drug Company and COPD Foundation
Lupin inches up on collaborating with Mark Cuban Cost Plus Drug Company and COPD Foundation
Source: Accord Fintech
7/09/2023 10:48:08 AM
India Resurgence Fund to acquire API and CRAMS business of Ind-Swift Laboratories for Rs 1,650 cr The board of directors of Ind-Swift Laboratories Limited on Wednesday approved a business transfer of its active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) to Synthimed Labs Private Limited (Synthimed), a portfolio company of India Resurgence Fund (IndiaRF).  IndiaRF, a leading India-focused investment platform promoted by Piramal Enterprises Limited and Bain Capital, will acquire the business for a consideration of Rs 1,650 crore. Ind...
India Resurgence Fund to acquire API and CRAMS business of Ind-Swift Laboratories for Rs 1,650 cr
India Resurgence Fund to acquire API and CRAMS business of Ind-Swift Laboratories for Rs 1,650 cr
Source: IANS
7/09/2023 10:19:41 AM
Ind-Swift Laboratories touches roof on the BSE Ind-Swift Laboratories is currently trading at its upper limit of Rs. 123.40, up by 20.55 points or 19.98% from its previous closing of Rs. 102.85 on the BSE. The scrip opened at Rs. 103.55 and has touched a high and low of Rs. 123.40 and Rs. 98.20 respectively. So far 199745 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 123.40 on 06-Sep-2023 and a 52 week low of Rs. 53.00 on 28-Oct-2022. Last one week high a...
Ind-Swift Laboratories touches roof on the BSE
Ind-Swift Laboratories touches roof on the BSE
Source: Accord Fintech
6/09/2023 3:07:13 PM
Cipla trades higher on the BSE Cipla is currently trading at Rs. 1249.95, up by 11.40 points or 0.92% from its previous closing of Rs. 1238.55 on the BSE. The scrip opened at Rs. 1251.95 and has touched a high and low of Rs. 1266.20 and Rs. 1244.75 respectively. So far 47007 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs...
Cipla trades higher on the BSE
Cipla trades higher on the BSE
Source: Accord Fintech
6/09/2023 1:50:50 PM
Cipla rises as its arm to acquire 100% stake in Actor Pharma Cipla is currently trading at Rs. 1241.20, up by 2.30 points or 0.19% from its previous closing of Rs. 1238.90 on the BSE. The scrip opened at Rs. 1255.90 and has touched a high and low of Rs. 1265.00 and Rs. 1238.80 respectively. So far 51953 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1277.55 on 10-Aug-2023 and a 52 week low of Rs. 852.00 on 22-Mar-2023. Last one week high and low of the scrip stood at Rs....
Cipla rises as its arm to acquire 100% stake in Actor Pharma
Cipla rises as its arm to acquire 100% stake in Actor Pharma
Source: Accord Fintech
5/09/2023 11:17:44 AM
Pharma companies likely to maintain momentum on growth, profitability in regulated markets: Ind-Ra Amid new launches, ongoing drug shortages and growth opportunities in the domestic formulation business, credit rating agency India Ratings and Research (Ind-Ra) in its latest report has stated that its rated pharma companies are likely to maintain the momentum on growth and profitability in regulated markets (US). As per the report, normalisation of drug prices in the US and a softening in raw material prices will help companies to keep revenue growth of 10% and EBITDA margin of about 21%...
Pharma companies likely to maintain momentum on growth, profitability in regulated markets: Ind-Ra
Pharma companies likely to maintain momentum on growth, profitability in regulated markets: Ind-Ra
Source: Accord Fintech
4/09/2023 1:52:40 PM
Shilpa Medicare rises on getting marketing authorization for Betahistine Dihydrochloride Orodispersible Films Shilpa Medicare is currently trading at Rs. 374.05, up by 3.10 points or 0.84% from its previous closing of Rs. 370.95 on the BSE. The scrip opened at Rs. 379.40 and has touched a high and low of Rs. 381.45 and Rs. 370.60 respectively. So far 26857 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 425.00 on 08-Sep-2022 and a 52 week low of Rs. 222.40 on 28-Mar-2023. Last one week high and low of the scrip stood at...
Shilpa Medicare rises on getting marketing authorization for Betahistine Dihydrochloride Orodispersible Films
Shilpa Medicare rises on getting marketing authorization for Betahistine Dihydrochloride Orodispersible Films
Source: Accord Fintech
4/09/2023 12:21:39 PM
Natco Pharma gains on making strategic investment in ISCA Inc Natco Pharma is currently trading at Rs. 911.00, up by 6.60 points or 0.73% from its previous closing of Rs. 904.40 on the BSE. The scrip opened at Rs. 918.35 and has touched a high and low of Rs. 918.35 and Rs. 899.90 respectively. So far 9278 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 920.00 on 10-Aug-2023 and a 52 week low of Rs. 502.00 on 02-Feb-2023. Last one week high and low of the scrip stood at Rs....
Natco Pharma gains on making strategic investment in ISCA Inc
Natco Pharma gains on making strategic investment in ISCA Inc
Source: Accord Fintech
31/08/2023 11:38:42 AM
Ajanta Pharma zooms on getting USFDA`s final nod for Topiramate Extended-Release Capsules Ajanta Pharma is currently trading at Rs. 1782.60, up by 54.10 points or 3.13% from its previous closing of Rs. 1728.50 on the BSE. The scrip opened at Rs. 1750.05 and has touched a high and low of Rs. 1800.00 and Rs. 1750.05 respectively. So far 26 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1804.70 on 17-Aug-2023 and a 52 week low of Rs. 1115.15 on 28-Oct-2022. Last one week high and low of the scrip stood...
Ajanta Pharma zooms on getting USFDA`s final nod for Topiramate Extended-Release Capsules
Ajanta Pharma zooms on getting USFDA`s final nod for Topiramate Extended-Release Capsules
Source: Accord Fintech
31/08/2023 10:00:13 AM
Strides Pharma Science moves up as its arm gets USFDA`s nod for Mycophenolate Mofetil for Oral Suspension Strides Pharma Science is currently trading at Rs. 437.95, up by 2.00 points or 0.46% from its previous closing of Rs. 435.95 on the BSE. The scrip opened at Rs. 435.10 and has touched a high and low of Rs. 445.75 and Rs. 435.10 respectively. So far 6078 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 488.85 on 01-Aug-2023 and a 52 week low of Rs. 268.40 on 21-Mar-2023. Last one week high and low of the scrip s...
Strides Pharma Science moves up as its arm gets USFDA`s nod for Mycophenolate Mofetil for Oral Suspension
Strides Pharma Science moves up as its arm gets USFDA`s nod for Mycophenolate Mofetil for Oral Suspension
Source: Accord Fintech
30/08/2023 12:47:16 PM
Unichem Laboratories moves up on getting ANDA approval for Prasugrel Tablets Unichem Laboratories is currently trading at Rs. 418.25, up by 1.15 points or 0.28% from its previous closing of Rs. 417.10 on the BSE. The scrip opened at Rs. 422.00 and has touched a high and low of Rs. 422.00 and Rs. 415.75 respectively. So far 1799 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 467.00 on 03-Nov-2022 and a 52 week low of Rs. 265.00 on 25-Jan-2023. Last one week high and low of the scrip stoo...
Unichem Laboratories moves up on getting ANDA approval for Prasugrel Tablets
Unichem Laboratories moves up on getting ANDA approval for Prasugrel Tablets
Source: Accord Fintech
30/08/2023 12:45:32 PM
Lupin moves up as its arm launches Propranolol LA capsules Lupin is currently trading at Rs. 1106.00, up by 8.95 points or 0.82% from its previous closing of Rs. 1097.05 on the BSE. The scrip opened at Rs. 1118.15 and has touched a high and low of Rs. 1118.15 and Rs. 1103.60 respectively. So far 4648 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1143.70 on 17-Aug-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022. Last one week high and low of the scrip stood at Rs. ...
Lupin moves up as its arm launches Propranolol LA capsules
Lupin moves up as its arm launches Propranolol LA capsules
Source: Reuters
30/08/2023 9:59:49 AM
Buy Piramal Enterprises Ltd For Target Rs.1,230 - Emkay Global Financial Services Piramal Enterprises (PIEL) hosted its Investor Day on August 28, where the top management reaffirmed its earlier-stated ambition to double FY23 loan AUM by FY28 (Rs1.2-1.3trn) and deliver a consolidated RoA of ~3%. Importantly, the strategy to achieve this medium-term target was also reiterated as being a 70:30 retail to wholesale AUM mix. In retail, the approach is multiproduct offering to target the customers of Bharat without directly competing with large banks; while in wholesale, the foc...
Buy Piramal Enterprises Ltd For Target Rs.1,230 - Emkay Global Financial Services
Buy Piramal Enterprises Ltd For Target Rs.1,230 - Emkay Global Financial Services
Source: Emkay Global Financial Services Ltd
29/08/2023 2:50:37 PM
Lupin soars on getting USFDA`s nod for Pirfenidone Tablets Lupin is currently trading at Rs. 1096.70, up by 19.15 points or 1.78% from its previous closing of Rs. 1077.55 on the BSE. The scrip opened at Rs. 1077.55 and has touched a high and low of Rs. 1097.40 and Rs. 1076.05 respectively. So far 20162 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1143.70 on 17-Aug-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022. Last one week high and low of the scrip stood at Rs...
Lupin soars on getting USFDA`s nod for Pirfenidone Tablets
Lupin soars on getting USFDA`s nod for Pirfenidone Tablets
Source: Accord Fintech
28/08/2023 2:43:57 PM
Venus Remedies shines on getting marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes Venus Remedies is currently trading at Rs. 244.20, up by 11.55 points or 4.96% from its previous closing of Rs. 232.65 on the BSE. The scrip opened at Rs. 223.30 and has touched a high and low of Rs. 244.25 and Rs. 222.45 respectively. So far 8732 shares were traded on the counter. The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 301.80 on 10-Jul-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023. Last one week high and low of the scrip stood at...
Venus Remedies shines on getting marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes
Venus Remedies shines on getting marketing approval from Saudi Arabia for Enoxaparin in pre-filled syringes
Source: Accord Fintech
28/08/2023 2:40:52 PM
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services US/EU markets drive profitability Re-exploring restructuring of Eugia business * Aurobindo Pharma (ARBP) delivered operationally better-than-expected 1QFY24 performance, on the back of a healthy volume off-take in the US as well as the EU market. With improved outlook, ARBP has re-started the exercise to restructure the Eugia business and evaluate options to unlock the inherent value of its injectable business. * We raise our earnings estimate by 8%/7% for FY24/FY25, factoring a) su...
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
26/08/2023 12:56:15 PM
Neutral Divi`s Laboratories Ltd For Target Rs. 3,430 - Motilal Oswal Financial Services Margin recovers; sales yet to pick up Work-in-progress for greenfield project at Kakinada * The operational performance of Divi’s Laboratories (DIVI) missed our estimates marginally in 1QFY24, due to lower sales in generics and custom synthesis. However, EBITDA margin expanded sequentially owing to lower raw material/logistics costs. * We reduce our earnings estimates for FY24/FY25 by 3%/5% to account for a gradual off-take in custom synthesis/nutraceutical sales in the near te...
Neutral Divi`s Laboratories Ltd For Target Rs. 3,430 - Motilal Oswal Financial Services
Neutral Divi`s Laboratories Ltd For Target Rs. 3,430 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
26/08/2023 12:32:53 PM
PM Narendra Modi highlights initiatives to push business at meeting with corporates in Athens Prime Minister Narendra Modi on Friday highlighted India's progress in areas such as renewables, startups, pharma, IT, digital payments and infrastructure and the various initiatives undertaken to foster business, during his interaction with industry representatives in Athens at a business lunch hosted by Greek Prime Minister Kyriakos Mitsotakis.  PM Modi acknowledged the role played by industry leaders in strengthening bilateral relations and promoting economic cooperation betwee...
PM Narendra Modi highlights initiatives to push business at meeting with corporates in Athens
PM Narendra Modi highlights initiatives to push business at meeting with corporates in Athens
Source: IANS
26/08/2023 8:41:13 AM
Sudarshan Pharma Industries rises on incorporating subsidiary company Sudarshan Pharma Industries is currently trading at Rs. 82.80, up by 1.25 points or 1.53% from its previous closing of Rs. 81.55 on the BSE. The scrip opened at Rs. 82.50 and has touched a high and low of Rs. 82.80 and Rs. 82.50 respectively. So far 8000 shares were traded on the counter. The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 91.90 on 23-Aug-2023 and a 52 week low of Rs. 51.85 on 31-Mar-2023. Last one week high and low of the scrip sto...
Sudarshan Pharma Industries rises on incorporating subsidiary company
Sudarshan Pharma Industries rises on incorporating subsidiary company
Source: Accord Fintech
25/08/2023 2:46:59 PM
Generic drug prescription mandate unlikely to impact profitability of Indian pharma companies: Fitch Ratings Fitch Ratings in its latest report has said that the government guidelines mandating physicians prescribe only generic drug names face execution challenges and are unlikely to impact profitability of pharmaceutical companies in Indian market. It also said the domestic pharmaceutical market is mainly a branded generics market in which pharma companies sell off-patented drugs under their own brand names with varying prices. According to the report, a sizeable erosion in branded generics sale...
Generic drug prescription mandate unlikely to impact profitability of Indian pharma companies: Fitch Ratings
Generic drug prescription mandate unlikely to impact profitability of Indian pharma companies: Fitch Ratings
Source: Accord Fintech
25/08/2023 12:12:46 PM
Granules India shines on getting nod from Brazilian Health Regulatory Agency Granules India is currently trading at Rs. 299.85, up by 5.05 points or 1.71% from its previous closing of Rs. 294.80 on the BSE. The scrip opened at Rs. 296.85 and has touched a high and low of Rs. 300.60 and Rs. 295.20 respectively. So far 3035 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023. Last one week high and low of the scrip stood at R...
Granules India shines on getting nod from Brazilian Health Regulatory Agency
Granules India shines on getting nod from Brazilian Health Regulatory Agency
Source: Accord Fintech
25/08/2023 10:13:56 AM
Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd Revenue surged, Margins Improved Zydus Lifesciences Ltd. is one of India’s leading vertically integrated pharmaceutical companies, with presence across the value chain, from manufacturing of finished dosage forms to active pharmaceutical ingredients, animal healthcare products, and wellness products. ? In Q1FY24, the company’s consolidated revenue rose a significant 29.6% YoY to Rs. 5,140cr, primarily propelled by the US formulations business, which surged 57.4% YoY. ? EBITDA a...
Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd
Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd
Source: Geojit Financial Services Ltd
24/08/2023 2:35:59 PM
Gland Pharma trades higher on the BSE Gland Pharma is currently trading at Rs. 1587.75, up by 6.40 points or 0.40% from its previous closing of Rs. 1581.35 on the BSE. The scrip opened at Rs. 1590.05 and has touched a high and low of Rs. 1627.45 and Rs. 1585.55 respectively. So far 18174 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2606.00 on 02-Sep-2022 and a 52 week low of Rs. 861.50 on 22-May-2023. Last one week high and low of the scrip stood...
Gland Pharma trades higher on the BSE
Gland Pharma trades higher on the BSE
Source: Accord Fintech
24/08/2023 12:20:25 PM
Auro Laboratories zooms on getting nod for capacity expansion Auro Laboratories is currently trading at Rs. 93.57, up by 10.87 points or 13.14% from its previous closing of Rs. 82.70 on the BSE. The scrip opened at Rs. 84.79 and has touched a high and low of Rs. 94.75 and Rs. 84.79 respectively. So far 111325 shares were traded on the counter. The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 99.00 on 19-May-2023 and a 52 week low of Rs. 52.50 on 31-Mar-2023. Last one week high and low of the scrip stood at ...
Auro Laboratories zooms on getting nod for capacity expansion
Auro Laboratories zooms on getting nod for capacity expansion
Source: Accord Fintech
24/08/2023 11:06:32 AM
Torrent Pharmaceuticals moves up on getting EIR for Dahej manufacturing facility Torrent Pharmaceuticals is currently trading at Rs. 1950.40, up by 14.95 points or 0.77% from its previous closing of Rs. 1935.05 on the BSE.  The scrip opened at Rs. 1960.05 and has touched a high and low of Rs. 1967.90 and Rs. 1945.10 respectively. So far 2512 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2099.95 on 10-Aug-2023 and a 52 week low of Rs. 1446.15 on 01-Mar-2023. Last one week high and low ...
Torrent Pharmaceuticals moves up on getting EIR for Dahej manufacturing facility
Torrent Pharmaceuticals moves up on getting EIR for Dahej manufacturing facility
Source: Accord Fintech
24/08/2023 10:08:24 AM
Piramal Enterprises gains on getting nod to raise up to Rs 3000 crore through NCDs Piramal Enterprises is currently trading at Rs. 1067.40, up by 8.45 points or 0.80% from its previous closing of Rs. 1058.95 on the BSE. The scrip opened at Rs. 1061.95 and has touched a high and low of Rs. 1079.85 and Rs. 1061.05 respectively. So far 37338 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,202.73 on 26-Aug-2022 and a 52 week low of Rs. 630.20 on 28-Mar-2023. Last one week high and low of the scr...
Piramal Enterprises gains on getting nod to raise up to Rs 3000 crore through NCDs
Piramal Enterprises gains on getting nod to raise up to Rs 3000 crore through NCDs
Source: Accord Fintech
23/08/2023 12:15:41 PM
pharma Sector Update : Few good approvals amidst many routine ones By Yes Securities Few good approvals amidst many routine ones We take a look at US approvals data between June to August 2023 to better assess traction in US business amidst a generally positive and benign pricing environment. Overall, companies have netted about 8-9 good approvals mostly shared between Alembic, Aurobindo and Zydus. Alkem and Ajanta do have a decent approval each in last few months which should support their US growth QoQ. More broadly, FDA approvals continue to be of fairly commoditized va...
pharma Sector Update : Few good approvals amidst many routine ones By Yes Securities
pharma Sector Update : Few good approvals amidst many routine ones By Yes Securities
Source: Yes Securities Ltd
23/08/2023 11:40:39 AM
Marksans Pharma trades higher on the BSE Marksans Pharma is currently trading at Rs. 113.85, up by 0.75 points or 0.66% from its previous closing of Rs. 113.10 on the BSE. The scrip opened at Rs. 114.10 and has touched a high and low of Rs. 115.50 and Rs. 113.65 respectively. So far 39430 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 122.50 on 10-Aug-2023 and a 52 week low of Rs. 45.65 on 11-Oct-2022. Last one week high and low of the scrip stood at ...
Marksans Pharma trades higher on the BSE
Marksans Pharma trades higher on the BSE
Source: Accord Fintech
23/08/2023 11:07:09 AM
Marksans Pharma jumps on getting USFDA`s final approval for Guaifenesin Extended-Release Tablets Marksans Pharma is currently trading at Rs. 112.75, up by 3.05 points or 2.78% from its previous closing of Rs. 109.70 on the BSE. The scrip opened at Rs. 110.00 and has touched a high and low of Rs. 114.75 and Rs. 110.00 respectively. So far 308136 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 122.50 on 10-Aug-2023 and a 52 week low of Rs. 45.65 on 11-Oct-2022. Last one week high and low of the scrip stood at...
Marksans Pharma jumps on getting USFDA`s final approval for Guaifenesin Extended-Release Tablets
Marksans Pharma jumps on getting USFDA`s final approval for Guaifenesin Extended-Release Tablets
Source: Accord Fintech
22/08/2023 3:22:27 PM
Cian Healthcare zooms on entering into agreement with CHI Pharmaceuticals, Nigeria Cian Healthcare is currently trading at Rs. 25.58, up by 1.68 points or 7.03% from its previous closing of Rs. 23.90 on the BSE. The scrip opened at Rs. 23.80 and has touched a high and low of Rs. 25.58 and Rs. 23.80 respectively. So far 30000 shares were traded on the counter. The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 41.10 on 31-May-2023 and a 52 week low of Rs. 13.55 on 22-Aug-2022. Last one week high and low of the scrip stood at Rs. 2...
Cian Healthcare zooms on entering into agreement with CHI Pharmaceuticals, Nigeria
Cian Healthcare zooms on entering into agreement with CHI Pharmaceuticals, Nigeria
Source: Accord Fintech
22/08/2023 2:56:38 PM
Vadodara-based Shiva Pharmachem Limited files DRHP for its Rs 900 Crore IPO Vadodara-based Shiva Pharmachem , the largest manufacturer of acid and alkyl chlorides, by volume, in CY 2022 in India and a key player globally, with over 2 decades of experience in the Indian specialty chemicals business has filed its Draft Red Herring prospectus (DRHP) with capital market regulator Sebi to raise funds through for its initial public offering (IPO). The IPO with a face value of Rs 2 each is entirely an offer for sale (OFS) of up to Rs 900 crore by Promoter and Promoter Gr...
Vadodara-based Shiva Pharmachem Limited files DRHP for its Rs 900 Crore IPO
Vadodara-based Shiva Pharmachem Limited files DRHP for its Rs 900 Crore IPO
Source: PR Agency
22/08/2023 12:24:56 PM
Buy Vimta Labs Ltd For Target Rs.727 - Sushil Finance Food and pharma division to drive growth : Several branded drugs are set to lose their patent protection soon, which should aid the generic drugs market, leading to higher revenue-generating opportunities in the Vimta Labs (VLL) pharma space. The company has entered the full spectrum in clinical trial space with a 180-bed capacity in the laboratory, thereby expanding the services to existing clientele. In the food segment, imports and exports of food products drive the testing business. As...
Buy Vimta Labs Ltd For Target Rs.727 - Sushil Finance
Buy Vimta Labs Ltd For Target Rs.727 - Sushil Finance
Source: Sushil Finance Ltd
21/08/2023 3:01:15 PM
IIT Bhilai-led team develops new hydrogel-based insulin-delivery system   A team of researchers from the Indian Institutes of Technology (IIT) Bhilai has successfully engineered a novel hydrogel-based insulin-delivery platform, which can help patients with Type-1 diabetes better manage their conditions. Currently, an estimated three million people in India rely on insulin therapy, where they often resort to daily insulin injections using needles or specialised devices to manage their blood sugar levels. The hydrogel-based drug delivery system has th...
IIT Bhilai-led team develops new hydrogel-based insulin-delivery system
IIT Bhilai-led team develops new hydrogel-based insulin-delivery system
Source: IANS
21/08/2023 2:36:35 PM
Neutral Alkem Laboratories Ltd For Target3,810 - Motilal Oswal Financial Services International markets and lower RM cost drive earnings Bioscience off-take at a healthy pace * Alkem Laboratories (ALKEM) delivered better-than-expected 1QFY24 performance, fueled by superior traction in international markets. ALKEM’s business growth was broad-based within international markets including the US, Chile, the UK, Kazakhstan and the Philippines. * We cut our earnings estimates by 7%/1% for FY24/FY25, factoring in: a) unfavorable seasonality effect in domestic formu...
Neutral Alkem Laboratories Ltd For Target3,810 - Motilal Oswal Financial Services
Neutral Alkem Laboratories Ltd For Target3,810 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
18/08/2023 12:51:52 PM
Concord Biotech lists with 21% premium on the BSE Concord Biotech has debuted at Rs 900.05 on the BSE, up by 159.05 points or 21.46% from its issue price of Rs 741. The scrip is currently trading at Rs 937.00, up by 196.00 points or 26.45% from its issue price. It has touched a high and low of Rs 987.05 and Rs 900.00 respectively. So far 12.88 lakh shares were traded on the counter. The offering, which was open for subscription between August 4, 2023 and August 8, 2023 was subscribed 24.87 times. The issue price was fixed at Rs 741 per...
Concord Biotech lists with 21% premium on the BSE
Concord Biotech lists with 21% premium on the BSE
Source: Accord Fintech
18/08/2023 12:49:50 PM
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets Zydus Lifesciences is currently trading at Rs. 652.40, up by 7.75 points or 1.20% from its previous closing of Rs. 644.65 on the BSE. The scrip opened at Rs. 655.00 and has touched a high and low of Rs. 659.00 and Rs. 647.20 respectively. So far 18824 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets
Source: IANS
18/08/2023 10:23:30 AM
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion Shares of Indian biopharma company Concord Biotech climbed as much as 23.7% in their market debut on Friday, valuing it at 95.92 billion rupees ($1.15 billion). The company, which makes active pharmaceutical ingredients, the key biologically active elements in a drug, opened at 900.05 rupees compared with its initial public offer (IPO) price of 741 rupees. Indian benchmark indexes, the Nifty 50 and the S&P BSE Sensex, were down 0.5% each as of 10:02 a.m. IST. ($1 = 83.0800 Indian...
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion
Source: Reuters
18/08/2023 10:19:57 AM
Lupin shines on launching patient support program `Jeet` dedicated to heart-health Lupin is currently trading at Rs. 1136.30, up by 23.35 points or 2.10% from its previous closing of Rs. 1112.95 on the BSE. The scrip opened at Rs. 1129.95 and has touched a high and low of Rs. 1143.70 and Rs. 1123.95 respectively. So far 20646 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,143.70 on 17-Aug-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022. Last one week high and low of the scrip stood at R...
Lupin shines on launching patient support program `Jeet` dedicated to heart-health
Lupin shines on launching patient support program `Jeet` dedicated to heart-health
Source: Accord Fintech
17/08/2023 9:48:40 AM
Neutral Biocon Ltd For Target Rs. 240 - Motilal Oswal Financial Services Ltd Steady progress in generics/research services * Biocon (BIOS) delivered lower-than-estimated earnings in 1QFY24, mainly led by inferior performance in the biologics segment (57% of 1QFY24 sales). This was offset to some extent by a healthy show in generics and research services. BIOS continues to make efforts to enhance offerings and resolve regulatory issues in the biologics segment. * We cut our earnings estimates by 14%/5% for FY24/FY25, factoring in a) higher rebates for certain pro...
Neutral Biocon Ltd For Target Rs. 240 - Motilal Oswal Financial Services Ltd
Neutral Biocon Ltd For Target Rs. 240 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services
16/08/2023 12:49:56 PM
Lupin trades higher on receiving USFDA`s approval for Doxycycline Hyclate Delayed-Release Tablets Lupin is currently trading at Rs. 1091.25, up by 9.55 points or 0.88% from its previous closing of Rs. 1081.70 on the BSE. The scrip opened at Rs. 1094.75 and has touched a high and low of Rs. 1094.75 and Rs. 1078.60 respectively. So far 12461 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1108.95 on 09-Aug-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022. Last one week high and low of the scrip stood at Rs....
Lupin trades higher on receiving USFDA`s approval for Doxycycline Hyclate Delayed-Release Tablets
Lupin trades higher on receiving USFDA`s approval for Doxycycline Hyclate Delayed-Release Tablets
Source: Accord Fintech
16/08/2023 11:29:20 AM
Buy Alkem Labs Ltd For Target Rs.4,242 - Sushil Finance Ltd Alkem Laboratories Ltd. We have coverage on Alkem Laboratories Ltd with a BUY rating on stock. Since our report, the stock has posted a high of Rs.4,206 today. With the recent run-up in the share price (20% return), we are now changing our rating on the stock to Neutral and recommend our investors to start booking profits.   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.sushilfinance.com/Disclamier/disclaimer ...
Buy Alkem Labs Ltd For Target Rs.4,242 - Sushil Finance Ltd
Buy Alkem Labs Ltd For Target Rs.4,242 - Sushil Finance Ltd
Source: Sushil Finance Ltd
15/08/2023 4:13:05 PM
Sell Alkem Labs Ltd For Target Rs. 3,500 - Yes Securities Slower domestic growth, US rise not a healthy mix; D/G to SELL Result Synopsis Alkem reported beat on topline though the driver was sharp jump in US and ROW markets while domestic lagged at +7% YoY. We note company lagged IPM in key covered therapies like gastro and vitamins in Q1. Notably, July is off to a weak start and company has downgraded domestic growth to 7-8% vs double digit earlier. US growth appeared high but only because Q1 FY23 had a low base eroded by severe price erosion;...
Sell Alkem Labs Ltd For Target Rs. 3,500 - Yes Securities
Sell Alkem Labs Ltd For Target Rs. 3,500 - Yes Securities
Source: Motilal Oswal Financial Services
15/08/2023 12:56:48 PM
Neutral Glenmark Pharma Ltd For Target Rs. 780 - Motilal Oswal Encouraging traction in Ryaltris across focus markets * Glenmark Pharma (GNP)’s 1QFY24 operational performance beat our estimates, led by strong performance in EU/ROW markets. Lower R&D spending resulted in margin expansion YoY as well as QoQ. * We raise our earnings estimates by 4%/3% for FY24/FY25, factoring in strong off-take in the respiratory portfolio in EU, increased traction in Ryaltris across focus markets, and healthy traction in the consumer care segment within the ...
Neutral Glenmark Pharma Ltd For Target Rs. 780 - Motilal Oswal
Neutral Glenmark Pharma Ltd For Target Rs. 780 - Motilal Oswal
Source: Motilal Oswal Financial Services
15/08/2023 11:17:38 AM
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services US/EU markets drive profitability Re-exploring restructuring of Eugia business * Aurobindo Pharma (ARBP) delivered operationally better-than-expected 1QFY24 performance, on the back of a healthy volume off-take in the US as well as the EU market. With improved outlook, ARBP has re-started the exercise to restructure the Eugia business and evaluate options to unlock the inherent value of its injectable business. * We raise our earnings estimate by 8%/7% for FY24/FY25, factoring a) superi...
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
15/08/2023 11:10:34 AM
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal US quarterly revenue at historical high Work in progress to enhance product pipeline * Zydus Life Sciences (ZYDUSLIF) beat our earnings estimates in 1QFY24, aided by strong traction in exports to the US and EU, and healthy YoY growth in the domestic formulation (DF) and API segments. * We raise our FY24/FY25 earnings estimates by 8%/4% to factor in niche product launches in the US generics segment, seasonal impact on consumer healthcare brands, and DF segment growth in line with mark...
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal
Source: Motilal Oswal Financial Services
14/08/2023 2:58:42 PM
India`s Divi`s Labs Q1 profit slumps on drug pricing pressures Indian pharmaceutical company Divi's Laboratories reported a 49.2% fall in quarterly profit, missing analysts' estimates, as the generic drug maker grappled with pricing pressures in key markets like the United States. The company reported a consolidated profit of 3.56 billion rupees ($42.9 million) for the first quarter ended June 30, compared to 7.02 billion rupees a year ago. Analysts, on an average, had expected a profit of 4.17 billion rupees, according to Refinitiv data. ...
India`s Divi`s Labs Q1 profit slumps on drug pricing pressures
India`s Divi`s Labs Q1 profit slumps on drug pricing pressures
Source: Reuters
14/08/2023 2:33:00 PM